Technical Analysis for DMAC - DiaMedica Therapeutics Inc.

Grade Last Price % Change Price Change
D 2.85 -5.94% -0.18
DMAC closed down 5.94 percent on Monday, March 18, 2024, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
Earnings due: Mar 26
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 200 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
BB Squeeze Ended Range Expansion 0.00%
Gapped Down Weakness 0.00%
Crossed Above 20 DMA Bullish -5.94%
Crossed Above 200 DMA Bullish -5.94%
Crossed Above 50 DMA Bullish -5.94%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 11 hours ago
200 DMA Resistance about 11 hours ago
50 DMA Resistance about 11 hours ago
Fell Below Previous Day's Low about 11 hours ago
Possible Inside Day about 12 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Kidney Disease Stroke Dementia Ischemia Kallikrein Pancreatitis Acute Pancreatitis

Is DMAC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.75
52 Week Low 1.46
Average Volume 39,259
200-Day Moving Average 2.94
50-Day Moving Average 2.93
20-Day Moving Average 2.97
10-Day Moving Average 2.98
Average True Range 0.16
RSI (14) 44.13
ADX 22.79
+DI 23.36
-DI 14.92
Chandelier Exit (Long, 3 ATRs) 2.80
Chandelier Exit (Short, 3 ATRs) 3.26
Upper Bollinger Bands 3.17
Lower Bollinger Band 2.77
Percent B (%b) 0.2
BandWidth 13.32
MACD Line 0.00
MACD Signal Line 0.02
MACD Histogram -0.0188
Fundamentals Value
Market Cap 108.17 Million
Num Shares 38 Million
EPS -0.60
Price-to-Earnings (P/E) Ratio -4.75
Price-to-Sales 0.00
Price-to-Book 2.16
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.02
Resistance 3 (R3) 3.03 3.00 2.99
Resistance 2 (R2) 3.00 2.95 2.99 2.98
Resistance 1 (R1) 2.92 2.93 2.91 2.91 2.97
Pivot Point 2.89 2.89 2.88 2.88 2.89
Support 1 (S1) 2.81 2.84 2.80 2.80 2.73
Support 2 (S2) 2.78 2.82 2.77 2.72
Support 3 (S3) 2.70 2.78 2.71
Support 4 (S4) 2.69